Your SlideShare is downloading. ×
Prescribing influences type 2 diabetes opportunities in type 2 diabetes for drugs with both safety and efficacy
Prescribing influences type 2 diabetes opportunities in type 2 diabetes for drugs with both safety and efficacy
Prescribing influences type 2 diabetes opportunities in type 2 diabetes for drugs with both safety and efficacy
Prescribing influences type 2 diabetes opportunities in type 2 diabetes for drugs with both safety and efficacy
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Prescribing influences type 2 diabetes opportunities in type 2 diabetes for drugs with both safety and efficacy

311

Published on

Datamonitor surveyed 199 primary care physicians and specialists across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) on their type 2 diabetes prescribing …

Datamonitor surveyed 199 primary care physicians and specialists across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) on their type 2 diabetes prescribing influences and how different classes perform. Key unmet needs in type 2 diabetes are discussed, as are general influences such as reimbursement status and inclusion in guidelines.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
311
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Prescribing Influences: Type 2 Diabetes – Opportunities in type 2 diabetes fordrugs with both safety and efficacyPublished:September 2011No.Of Pages:76Price:US $ 3800IntroductionDatamonitor surveyed 199 primary care physicians and specialists across the seven majormarkets (the US, Japan, France, Germany, Italy, Spain, and the UK) on their type 2diabetes prescribing influences and how different classes perform. Key unmet needs in type2 diabetes are discussed, as are general influences such as reimbursement status andinclusion in guidelines.Features and benefits* Analyze key opinion leader insight into clinical and associated unmet needs in type 2diabetes.* Evaluate physician ratings of important prescribing influences among the seven majormarkets.* Compare physician-reported drug class performance on key influencers of therapy choice.* Gain insight into the differences between reasons to switch treatment regimes andreasons to initiate treatment.HighlightsSurvey respondents report that efficacy of glycemic control is the most important influenceon therapy choice in type 2 diabetes across all markets, but beyond this different countriesvary – for example, treatment cost is ranked second in the US but last in France, wherereimbursement is widely available.Metformin is the “best” antidiabetic drug as measured by performance on all prescribingcriteria. DPP-IV inhibitors rate more highly than sulfonylureas in some markets, while drugswithout a record of use are not highly rated. Physicians consider drugs’ overall performancerather than individual criteria.While safety and side-effect profile are key for choosing a drug or drug class in the firstplace, safety is rated least important in the decision to switch treatment regimes in type 2diabetes, with KOLs confirming that they are unlikely to change treatment for a well-controlled patient even if worrying safety data emerge.
  • 2. Table Of ContentsOVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsDiabetes reports in the seven major marketsPublished diabetes reportsUNMET NEEDS IN TYPE 2 DIABETESPhysician perceptions of unmet needsSpecialists seek more effective insulin use while PCPs target administration mode andgeneral drug efficacyNo single unmet need defines type 2 diabetes managementMarket unmet needsDiagnosis of type 2 diabetesPatient awareness and compliancePhysician education and guideline awarenessPatient and physician education on insulin useClinical unmet needs in type 2 diabetesImproved efficacy and safety balance in type 2 diabetesImproving cardiovascular mortalityDurability of therapy effectStability of glucose control and avoiding hypoglycemiaBetter therapy tolerability and weight reductionReduced insulin regimen complexity and easier blood glucose monitoringNon-injected insulinsPRESCRIBING INFLUENCESTreatment guidelinesADA/EASD Treatment GuidelinesTreatment targets in type 2 diabetesStandards of Medical Care 2011Other GuidelinesIncentive schemes and guidelinesFactors influencing treatment choicesEfficacy of glycemic control is most importantCost is second-ranked factor in the USNon-insulin class performance in meeting criteriaMetformin is the comparator for all other antidiabetic classesPrescribing influences are not independent, and physicians consider a drugs wholeperformanceKey prescribing influencesOverall drug ratingsFactors influencing treatment switching
  • 3. Safety concerns are not a strong reason to switch a well-controlled patient off a drugLack of HbA1c control is the main reason for therapy switching in most markets, but lessimportant in GermanyFactors affecting choice of insulinConcentration profile is main criterion for basal insulin selectionIndividual patient response is key for choosing mealtime insulinTrends in marketing strategiesMarketing strategy for leading brandsDisease management programsRisk-sharingReimbursementUS formulary tier status for leading brandsReimbursement in the EUBIBLIOGRAPHYJournal papers and conference proceedingsOther sourcesDatamonitor reportsAPPENDIXDatamonitor Type 2 Diabetes Physician SurveyContributing expertsReport methodologyLIST OF TABLESTable: ADA/EASD summary of glucose-lowering interventions, 2009Table: ADA evidence grading system for clinical practice recommendationsTable: Examples of diabetes support programs from major manufacturers, 2011Table: Representative formulary tier status in the US for leading brands in type 2 diabetes,2011Table: EU type 2 diabetes treatment reimbursement policies, 2011Table: Survey respondents in the seven major markets, by country and physician type,2011LIST OF FIGURESFigure: Rating of unmet needs in the seven major markets, by physician type, 2011Figure: Diagnosed type 2 diabetics as a percentage of prevalent patient population in theseven major markets, 2011Figure: Reasons for type 2 diabetes going undiagnosed in the seven major markets, 2011Figure: ADA/EASD algorithm for the metabolic management of type 2 diabetes, 2009Figure: Physician perceptions of the relative importance of drug characteristics forprescribing in type 2 diabetes in the seven major markets, 2011Figure: Physician perceptions of the relative importance of drug characteristics forprescribing in type 2 diabetes in the seven major markets, by country, 2011Figure: Physician perceptions of the relative importance of drug characteristics forprescribing in type 2 diabetes in the seven major markets, by physician type, 2011Figure: Physician grading of non-insulin classes in the seven major markets, 2011
  • 4. Figure: Physician grading of marketed non-insulin classes in the seven major markets, 2011Figure: Physician grading of pipeline non-insulin classes compared with metformin in theseven major markets, 2011Figure: Physician grading of non-insulin classes in the seven major markets, weighted byfactor importance, 2011Figure: Physician grading of non-insulin classes efficacy in the seven major markets, 2011Figure: Physician grading of non-insulin classes safety and side-effect profile in the sevenmajor markets, 2011Figure: Weighted grading of the non-insulin marketed and pipeline classes across allcriteria, in the seven major markets, 2011Figure: Weighted grading of the non-insulin marketed and pipeline classes across allcriteria, by country, in the seven major markets, 2011Figure: Influence of different factors on the decision to change patient treatment in theseven major markets, 2011Figure: Influence of different factors on the decision to change patient treatment in theseven major markets, by country, 2011Figure: Criteria for choosing a basal insulin in the seven major markets, 2011Figure: Criteria for choosing a basal insulin in the seven major markets, by country, 2011Figure: Criteria for choosing a prandial insulin in the seven major markets, 2011Figure: Criteria for choosing a prandial insulin in the seven major markets, by country, 2011About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×